Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Non-Small Cell Lung Cancer: Update Bulletin [November 2014]

Product Code:
596200303
Release Date:
November 2014
Format:
PDF

Gain new KOL insights on the latest events happening in Non-Small Cell Lung Cancer: ESMO 2014; AstraZeneca’s MEDI4736 and AZD9291, LUX-Lung 8 trial of Boehringer Ingelheim’s Gilotrif versus Roche/Astellas’ Tarceva, Boehringer Ingelheim’s nintedanib, (CHMP) for NSCLC; Authorisation Application (MAA) for Bristol-Myers Squibb, II/III trials of Merck/Oncothyreon's tecemotide and Eisai’s Halaven.

Highlights from this event update bulletin

  • How do KOLs view the potential benefits of Boehringer Ingelheim’s nintedanib for the treatment of prostate cancer?
  • What will be the major threats and opportunities for nintedanib in the NSCLC market?
  • How is AstraZeneca’s AZD9291 rated as a treatment for advanced EGFR-mutation positive NSCLC?
  • How do AstraZeneca’s AZD9291 and Clovis’ CO-1686 compare in terms of efficacy and tolerability?
  • How do KOLs view the results of the LUX-Lung 8 trial?
  • What are the chances of success for BMS’s Opdivo in the treatment of squamous NSCLC?
  • How do KOLs view the combination of AstraZeneca’s MEDI4736 and tremelimumab for the treatment of NSCLC?
  • Is there a future for Eisai’s Halaven in NSCLC treatment?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved